---
title: "Why Is Agenus Stock Falling on Tuesday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292652223.md"
description: "Agenus (AGEN) stock fell 7.60% on Tuesday due to short-term profit-taking following a massive 111% surge on Monday. This volatility followed positive Phase 1b clinical data for its botensilimab plus balstilimab combination and an $85 million private placement financing. HC Wainwright maintained a Buy rating with a $30 price target. Proceeds will fund the strategic shift to the Phase 3 ROBBIN trial, while short interest increased to 14.58% of the float."
datetime: "2026-07-14T15:37:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292652223.md)
  - [en](https://longbridge.com/en/news/292652223.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292652223.md)
generator: "portal-rs"
---

# Why Is Agenus Stock Falling on Tuesday?

**Agenus Inc.** (NASDAQ:AGEN) stock is trading lower on Tuesday due to short-term profit-taking following a record-breaking price surge on Monday, when the stock gained between 95% and 111%.

On Tuesday, **HC Wainwright & Co.** maintained its Buy rating on Agenus and raised its price target for the stock to $30. The updated analyst outlook follows significant clinical and financial updates released by the biotechnology firm on Monday morning.

 **• Agenus shares are sliding. What’s behind AGEN decline?**

## **Phase 1b Clinical Trial Results**

The volatility comes after Agenus reported updated three-year Phase 1b data on Monday. The trial evaluated its botensilimab plus balstilimab combination in 123 heavily pretreated patients with refractory microsatellite-stable metastatic colorectal cancer without active liver metastases.

The combination produced a median overall survival of 21.2 months. The 24-month and 36-month overall survival rates reached 41% and 33%, respectively. The data showed a confirmed objective response rate of 21% across 26 confirmed responses.

 **Read Also: Palantir CEO Alex Karp Warns AI Could Become America's Biggest Driver of Wealth Inequality: 'You Now Have a Revolution Where…'** 

## **Private Placement Financing Details**

Separately, Agenus announced a private placement led by **Commodore Capital**, with participation from **RA Capital Management**, **TCGX**, **Invus** and **Ligand Pharmaceuticals Inc**. The financing provides approximately $85 million in upfront gross proceeds, with up to an additional $255 million if accompanying warrants are fully exercised.

## **Strategic Shift to Phase 3 ROBBIN Trial**

The company stated the proceeds will fund its planned registrational Phase 3 ROBBIN trial, evaluating the combination as a neoadjuvant treatment in earlier-stage colon cancer. Agenus plans to discontinue financial support for its ongoing BATTMAN Phase 3 study to facilitate this strategic shift. The first patient dose in the ROBBIN trial is scheduled for the first quarter of 2027.

## **Agenus Stock Short Interest Report**

Short interest in Agenus rose during the latest reporting period, increasing from 4.78 million shares to 5.99 million shares. As a result, approximately 14.58% of the company’s public float is now sold short.

Based on the stock’s average daily trading volume of 1.11 million shares, it would take short sellers an estimated 5.42 days to cover their positions, assuming average trading activity and no significant increase in the share price.

**AGEN Stock Price Activity:** Agenus shares were down 7.60% at $5.66 at the time of publication on Tuesday, according to Benzinga Pro data.

 **Read Also: IBM Crashes 24%, Drags Tech and IT Services Stocks Into Selloff** 

*Image via Shutterstock/ K\_E\_N*

### Related Stocks

- [AGEN.US](https://longbridge.com/en/quote/AGEN.US.md)
- [PLTR.US](https://longbridge.com/en/quote/PLTR.US.md)
- [LGND.US](https://longbridge.com/en/quote/LGND.US.md)
- [IBM.US](https://longbridge.com/en/quote/IBM.US.md)
- [00847G804.US](https://longbridge.com/en/quote/00847G804.US.md)

## Related News & Research

- [Agenus posts investor deck spotlighting botensilimab-balstilimab neoadjuvant program in MSS colon cancer](https://longbridge.com/en/news/296536017.md)
- [Agenus extends $24.75 million loan maturity to Nov. 2029 in Ocean 1181 amendment](https://longbridge.com/en/news/296267258.md)
- [Agenus Inc. Reports No Material Changes to Previously Disclosed Risk Factors in Latest Review](https://longbridge.com/en/news/295365390.md)
- [NYSE:MMA - MMA.INC Completes US$4.0 Million Private Placement at US$1.00 Per Share | MMA Stock News](https://longbridge.com/en/news/296495505.md)
- [US, Jamaica Sign Status Of Forces Agreement To Fight Criminal Gangs, Narco-terrorists](https://longbridge.com/en/news/296606194.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**